Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityDomenica Rubino, Mark Warren|JAMA|2021Cited by 1.2k
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trialFilip K. Knop, W. Timothy Garvey, Ruben D do Vale et al.|The Lancet|2023Cited by 377